Evolution of the Average Target: NOV Inc.

Evolution of the Target Price: NOV Inc.

Changes in Analyst Recommendations: NOV Inc.

42f7d9b726673023b19.MvFl-J1w0a5CLLfQiZ0Rj9bF1Roy9lk6PHIjhOmyfr4.eqNRqNIigeUMdo6Fwcwp3pqJmXkExgNIVkdGvaHwIfQBxA6ZrDe7mTpU5g~56d2c2d3cddfa6c256c777560cf57f80
06-04 NOV Shares Rise After Capital One Upgrade MT
06-04 Capital One Upgrades NOV to Overweight From Equal Weight, Adjusts Price Target to $26 From $25 MT
04-30 Zephirin Cuts Price Target on NOV to $17 From $18, Keeps Hold Rating, Medium Risk MT
04-29 RBC Lifts Price Target on NOV to $22 From $21, Keeps Sector Perform Rating MT
04-14 NOV Offers Upside From Improved Offshore and Short-Cycle Activity but Better Alternatives Exist, RBC Says MT
04-14 RBC Downgrades NOV to Sector Perform From Outperform, Keeps $21 Price Target MT
04-14 Analyst recommendations: Biogen, Ford, Ge Vernova, Booking, Comcast… Zonebourse
02-23 Zephirin Downgrades NOV to Hold From Buy, Lifts Price Target to $18 From $17, Keeps Medium Risk MT
02-12 Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap… Zonebourse
02-04 Barclays Upgrades NOV to Equalweight From Underweight, Raises Price Target to $20 From $15 MT
02-04 Analyst recommendations: Booking, PayPal, Fedex, Gartner, Lockheed Martin…. Zonebourse
01-15 RBC Capital Adjusts NOV Price Target to $21 From $19, Maintains Outperform Rating MT
01-14 Analyst recommendations: Rivian, Applied Materials, Coinbase, Intel, Spotify… Zonebourse
11-20 Zephirin Lowers Price Target on NOV to $16 From $17, Keeps Buy Rating MT
29/10/25 RBC Raises Price Target on NOV to $19 From $17, Keeps Outperform Rating MT
09/10/25 RBC Lowers Price Target on NOV to $17 From $18, Keeps Outperform Rating MT
30/07/25 RBC Cuts Price Target on NOV to $18 From $19, Keeps Outperform Rating MT
29/07/25 NOV's Q2 revenue falls but beats expectations RE
15/05/25 Zephirin Cuts Price Target on NOV to $17 From $19, Keeps Buy Rating MT
30/04/25 RBC Trims Price Target on NOV to $19 From $20, Keeps Outperform Rating MT
24/03/25 Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH… Zonebourse
24/03/25 RBC Upgrades NOV to Outperform From Sector Perform, Maintains $22 Price Target MT
06/02/25 RBC Raises Price Target on NOV to $22 From $21, Keeps Sector Perform Rating MT
15/01/25 Evercore ISI Downgrades NOV to In Line From Outperform, Adjusts Price Target to $18 From $25 MT
06/01/25 Seaport Downgrades NOV to Neutral From Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+9.92%
+15.54%
+16.34%
+0.14%
+25.44%
+10.14%
+23.75%
+32.86%
+32.82%
+37.48%
Average +20.44%
Weighted average by Cap. +16.29%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
20.23USD
Average target price
22.24USD
Spread / Average Target
+9.92%
High Price Target
26.00USD
Spread / Highest target
+28.52%
Low Price Target
17.00USD
Spread / Lowest Target
-15.97%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA